Erin Wilson
Stock Analyst at Morgan Stanley
(1.89)
# 2,841
Out of 4,818 analysts
21
Total ratings
46.15%
Success rate
0.75%
Average return
Main Sectors:
Stocks Rated by Erin Wilson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RPD Rapid7 | Maintains: Equal-Weight | $33 → $26 | $23.26 | +11.78% | 6 | Apr 16, 2025 | |
| ALGN Align Technology | Maintains: Outperform | $715 → $732 | $177.47 | +312.46% | 3 | Jul 29, 2021 | |
| CRL Charles River Laboratories International | Maintains: Neutral | $352 → $385 | $109.04 | +253.08% | 1 | Jul 20, 2021 | |
| IQV IQVIA Holdings | Maintains: Outperform | $242 → $265 | $147.06 | +80.20% | 1 | Jul 20, 2021 | |
| MEDP Medpace Holdings | Maintains: Outperform | $200 → $205 | $290.54 | -29.44% | 1 | Jul 20, 2021 | |
| ICLR ICON Public Limited Company | Maintains: Outperform | $245 → $250 | $143.12 | +74.68% | 2 | Jul 20, 2021 | |
| ELAN Elanco Animal Health | Upgrades: Outperform | $33 → $38 | $9.21 | +312.60% | 1 | Feb 26, 2021 | |
| FLGT Fulgent Genetics | Downgrades: Underperform | n/a | $18.95 | - | 1 | Jan 8, 2021 | |
| TMO Thermo Fisher Scientific | Initiates: Neutral | $341 | $431.64 | -21.00% | 1 | Jan 22, 2020 | |
| INCR InterCure | Maintains: Outperform | $68 → $54 | $1.46 | +3,598.63% | 4 | Nov 14, 2017 |
Rapid7
Apr 16, 2025
Maintains: Equal-Weight
Price Target: $33 → $26
Current: $23.26
Upside: +11.78%
Align Technology
Jul 29, 2021
Maintains: Outperform
Price Target: $715 → $732
Current: $177.47
Upside: +312.46%
Charles River Laboratories International
Jul 20, 2021
Maintains: Neutral
Price Target: $352 → $385
Current: $109.04
Upside: +253.08%
IQVIA Holdings
Jul 20, 2021
Maintains: Outperform
Price Target: $242 → $265
Current: $147.06
Upside: +80.20%
Medpace Holdings
Jul 20, 2021
Maintains: Outperform
Price Target: $200 → $205
Current: $290.54
Upside: -29.44%
ICON Public Limited Company
Jul 20, 2021
Maintains: Outperform
Price Target: $245 → $250
Current: $143.12
Upside: +74.68%
Elanco Animal Health
Feb 26, 2021
Upgrades: Outperform
Price Target: $33 → $38
Current: $9.21
Upside: +312.60%
Fulgent Genetics
Jan 8, 2021
Downgrades: Underperform
Price Target: n/a
Current: $18.95
Upside: -
Thermo Fisher Scientific
Jan 22, 2020
Initiates: Neutral
Price Target: $341
Current: $431.64
Upside: -21.00%
InterCure
Nov 14, 2017
Maintains: Outperform
Price Target: $68 → $54
Current: $1.46
Upside: +3,598.63%